VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
NAGENiagen Bioscience Inc
$3.42$272M
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
HomeStocksNAGECash Flow

Niagen Bioscience Inc (NAGE) Cash Flow Statement

19Y historyFree accessUpdated daily

Cash conversion efficiency remains inconsistent, as evidenced by an operating cash flow to net income ratio of -0.19 in 2026Q1 and a $5.1 million negative change in working capital.

NAGE Cash Flow Statement

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09Dec'08Dec'07
Cash from Operations4.37M13.44M12.11M7.12M-15.1M-24.16M-10.6M-20.44M-20.91M-9.8M-2.94M-2.11M-2.58M-3.91M-10.12M-4.1M-2.66M-396.17K-1.92M-38.48K
Operating CF Margin %-10.38%12.16%8.52%-20.95%-35.82%-17.89%-44.15%-66.25%-46.24%-13.55%-11.8%-16.85%-38.44%-87.16%-50.52%-35.18%-6.86%-42.64%-
Operating CF Growth %371.25%10.97%70.14%147.14%37.52%-127.95%48.14%2.24%-113.26%-233.86%-39.1%18.19%33.94%61.4%-146.89%-54%-571.82%79.38%-4892.78%-
Net Income18.64M17.38M8.55M-4.94M-16.54M-27.13M-19.93M-32.15M-33.32M-11.38M-2.93M-2.77M-5.39M-4.42M-11.66M-7.89M-2.05M-907.57K-2.1M-38.38K
Depreciation & Amortization1.71M1.45M1.48M1.71M1.88M1.63M1.51M1.52M842K716K419.56K330.55K258.31K269.71K344.03K398.88K387.41K394.5K376.28K0
Stock-Based Compensation1.49M03.66M4.75M5.74M6.2M6.94M7.17M6.37M4.61M1.19M1.98M2.92M1.29M2.7M2.97M1.26M205.86K121.19K0
Deferred Taxes00000000000000000000
Other Non-Cash Items-1.36M2.9M-4.71M977K-167K-124K-204K2.59M4K-5.75M1.14M557.42K144.53K-330K1.94K133.5K20.64K-55433.05K0
Working Capital Changes-16.1M-8.3M3.13M4.62M-6.01M-4.73M1.08M427K5.19M2M-2.77M-2.21M-511.99K-714.11K-1.51M294.62K-2.28M-88.41K-347.41K-101
Change in Receivables-6.21M-756K-1.28M2.25M-3.32M-2.58M-555K-44K1.11M937K-4.11M-873.73K-881.7K1.35M-1.22M277.9K-503.63K-148.88K26.18K0
Change in Inventory-13.21M-11.63M5.33M152K-1.08M-1.92M-148K-3.29M-2.45M2.18M240.85K-4.44M-1.53M-466.35K-2.3M-1.48M-500.27K-211.18K-213.95K0
Change in Payables2.65M2.27M-1.07M553K-744K978K-181K78K5.83M-2.36M-245.67K2.77M2.16M-1.62M1.18M1.74M-33.71K103.97K-56.2K0
Cash from Investing4.99M-292K-143K-143K-334K-409K-165K-249K-1.77M4.6M-1.72M-647.73K1.59M998.65K-76.56K-176.66K-199.14K-179.49K-495.81K0
Capital Expenditures-321K-292K-163K-148K-334K-409K-124K-743K-1.32M-1.17M-1.5M-525.23K-121.74K-137.35K-24.55K-150.66K-169.14K-184.49K-417.53K0
CapEx % of Revenue0.25%0.23%0.16%0.18%0.46%0.61%0.21%1.61%4.19%5.5%6.95%2.94%0.8%1.35%0.21%1.86%2.24%3.19%9.27%-
Acquisitions5.31M000000000001.84M225K000000
Investments--------------------
Other Investing0020K5K00-41K494K-454K5.77M-220K-122.5K-130K911K-52.01K-26K-30K5K-78.28K0
Cash from Financing1.58M6.98M5.37M-90K7.65M36.09M8.65M16.88M-90K48.95M754.27K4.34M2.69M4.65M10.3M2.47M4.62M-78.47K3.24M875
Debt Issued (Net)-9K-12K-11K-15K-16K-31K-272K9.72M-196K-608K-5.22M2.29M2.33M-108.42K-86.07K-81.71K-62.61K-78.47K-74.57K0
Equity Issued (Net)1.64M7M5.43M07.75M26.74M4.86M6.77M-404K46.59M5.72M1.97M02.98M10.22M03.49M03.31M875
Dividends Paid00000000000000000000
Share Repurchases-2.6M-251K000000-404K00000-8.2K000-959.62K0
Other Financing-53K0-52K-75K-77K9.38M4.07M388K510K2.96M258.68K79.85K364.28K1.78M160.56K2.55M1.19M08K0
Net Change in Cash10.93M20.13M17.34M6.88M-7.78M11.52M-2.12M-3.8M-22.77M43.75M-3.91M1.58M1.7M1.74M99.85K-1.81M1.76M-654.13K821.72K-37.61K
Free Cash Flow4.05M13.14M11.95M6.97M-15.43M-24.57M-10.74M-21.19M-22.36M-11.15M-4.66M-2.76M-2.83M-4.13M-10.2M-4.28M-2.86M-580.66K-2.42M-38.48K
FCF Margin %3.11%10.16%11.99%8.34%-21.42%-36.43%-18.13%-45.78%-70.86%-52.62%-21.52%-15.43%-18.49%-40.67%-87.82%-52.7%-37.81%-10.05%-53.64%-
FCF Growth %-79.27%10.04%71.42%145.16%37.2%-128.75%49.31%5.22%-100.45%-139.3%-68.96%2.59%31.46%59.47%-138.48%-49.46%-392.66%75.98%-6181.16%-
FCF per Share0.050.150.150.09-0.22-0.37-0.18-0.37-0.41-0.25-0.12-0.08-0.08-0.12-0.32-0.19-0.18-0.06-0.26-0.01
FCF Conversion (FCF/Net Income)0.22x0.77x1.42x-1.44x0.91x0.89x0.53x0.64x0.63x0.86x1.00x0.76x0.48x0.88x0.87x0.52x1.30x0.44x0.91x1.00x
Interest Paid001K2K1K1K13K33K41K57K261.74K427.59K75K34.33K29.01K32.14K36.07K070.08K0
Taxes Paid00000000000000000000

Key Metrics

Growth RegimeDecelerating
ProfitabilityModerate
Balance SheetHealthy
Cash FlowMixed
Top Statement Risk

Regulatory and Patent Litigation

Earnings Quality Lacks Cash Consistency

According to the provided financial data, NAGE's operating cash flow to net income ratio has fluctuated wildly, reaching a low of -0.19 in 2026Q1, which suggests that reported accounting profits are frequently decoupled from the actual cash generated by the company's core business operations.

The significant divergence between net income and operating cash flow indicates that earnings quality is heavily influenced by non-cash items or timing differences in accruals. Investors should monitor whether this volatility stems from aggressive revenue recognition or the lumpy nature of legal settlements that often distort the company's true cash-generating capacity.

Free Cash Flow Margin Volatility

As reported in financial statements, NAGE's free cash flow margin has experienced extreme swings, peaking at 29.2% in 2024Q4 before contracting to -4.0% in 2026Q1, highlighting a lack of predictable cash generation despite the company's recent shift toward positive operating margins in certain periods.

The inability to maintain positive free cash flow suggests that the business model remains sensitive to operational scaling challenges and high fixed costs. This inconsistency warrants further investigation into whether the company can achieve sustainable cash self-sufficiency without relying on external financing or equity-based compensation to bridge gaps.

Working Capital Swings Impair Liquidity

Based on reported figures, NAGE has faced persistent working capital headwinds, with negative changes in working capital reaching $5.1 million in 2026Q1, which indicates that cash is being trapped in inventory or delayed receivables rather than flowing efficiently through the company's balance sheet.

The recurring negative working capital adjustments suggest that the company may be struggling to manage its inventory cycles or collection processes effectively. This trend appears to be a primary driver of the company's cash flow volatility and may indicate that growth is becoming increasingly capital-intensive to sustain.

SBC and Legal Costs Obscure

Data from recent filings reveals that NAGE consistently utilizes stock-based compensation, with $1.5 million issued in 2025Q2 alone, which effectively masks the true cash-burn rate by substituting equity for cash expenses that would otherwise weigh on the company's reported operating cash flow metrics.

The reliance on stock-based compensation suggests that management is attempting to preserve cash, yet this practice dilutes shareholders and hides the true cost of operations. Analysts should adjust cash flow figures to account for these non-cash expenses to determine if the company is truly self-funding its growth initiatives.

NAGE — Frequently Asked Questions

Quick answers to the most common questions about buying NAGE stock.

How much cash does Niagen Bioscience Inc (NAGE) generate from operations?

Niagen Bioscience Inc (NAGE) generated $13.4M in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.

What is Niagen Bioscience Inc's free cash flow?

Niagen Bioscience Inc (NAGE) generated $13.1M in free cash flow in 2025. Free cash flow is the cash left over after capital expenditures, which can be used to pay dividends, repurchase shares, or pay down debt.

What is Niagen Bioscience Inc's capital expenditure (CapEx)?

Niagen Bioscience Inc (NAGE) spent $0.3M on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.

How does Niagen Bioscience Inc distribute cash to shareholders?

In 2025, Niagen Bioscience Inc (NAGE) spent $0.3M on share repurchases. This shows the company's commitment to returning capital to its equity investors.